Natriumvalproaat Chrono Aurobindo (Sodium Valproate)

Sodium valproate, the active ingredient in Natriumvalproaat Chrono Aurobindo, is an anticonvulsant presented as an oral tablet for systemic use. It is prescribed for the management of various seizure types, mood stabilization in bipolar disorder, and migraine prevention in adult patients.

GNH USA supplies Natriumvalproaat Chrono Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sodium valproate acts on neuronal excitability and is used in several neurological and psychiatric conditions. - Generalized and focal seizures: reduces seizure frequency and severity. - Bipolar disorder: stabilizes mood and prevents manic episodes. - Migraine prophylaxis: decreases the number of migraine attacks per month.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Nausea or gastrointestinal upset. - Tremor or mild motor incoordination. - Weight gain or increased appetite. - Hair loss or thinning. - Drowsiness or fatigue. - Elevated liver enzymes.

Serious or Rare Side Effects: - Hepatotoxicity, especially in children. - Pancreatitis, presenting with abdominal pain. - Severe thrombocytopenia or neutropenia. - Hyperammonemic encephalopathy. - Acute pancreatitis. - Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should assess patient history and monitor laboratory parameters. - Liver function: obtain baseline and periodic liver enzyme tests. - Blood counts: monitor complete blood count for thrombocytopenia. - Pregnancy: avoid use in pregnancy unless benefits outweigh risks (Category D). - Concomitant CNS depressants: use with caution as additive sedation may occur. - Alcohol: advise patients to limit intake due to increased hepatotoxic risk. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Sodium valproate can alter the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Carbamazepine: may reduce valproate levels and increase carbamazepine toxicity. - Lamotrigine: risk of severe skin reactions; dose adjustments required. - Warfarin: valproate may potentiate anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely): - Phenytoin: may increase valproate concentrations, requiring monitoring. - Topiramate: additive CNS depression may occur. - Oral contraceptives: valproate can reduce hormonal efficacy, consider alternative contraception.